⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphonic Acid SCHEMBL8679396 | 1.00 | — | — | |
| Phosphonic Acid SCHEMBL309982 | 1.00 | — | — | |
| Phosphonic Acid SCHEMBL5174404 | 1.00 | — | — | |
| Phosphonic Acid SCHEMBL25330767 | 0.94 | — | — | |
| Phosphonic Acid SCHEMBL5468942 | 0.94 | — | — | |
| Phosphonic Acid SCHEMBL28959519 | 0.94 | — | — | |
| Phosphonic Acid SCHEMBL7742187 | 0.94 | — | — | |
| Phosphonic Acid SCHEMBL5470708 | 0.94 | — | — | |
| Phosphonic Acid SCHEMBL15572223 | 0.94 | — | — | |
| Phosphonic Acid SCHEMBL11337542 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119948053-A | Anti-SARS-CoV-2 antigen binding polypeptides, polypeptide complexes, and methods of use thereof | 摩德斯医疗股份有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119836434-A | Anti-SARS-CoV-2 antigen binding polypeptides, polypeptide complexes, and methods of use thereof | 摩德斯医疗股份有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-116615450-A | Human monoclonal antibody against SARS-COV-2 and application thereof | UAB研究基金会 | 2023-08-18 | — | — | CN | claimed |
| CN-110066293-A | A kind of aminotrimethylenephosphonic acid aluminium and its preparation method and application | 金发科技股份有限公司 | 2019-07-30 | — | — | CN | claimed |
| CN-1217698-C | Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents | MAXIN PHARMACEUTICALS INC (US) | 2005-09-07 | — | — | CN | claimed |
| CN-1324245-A | Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents | MAXIN PHARMACEUTICALS INC (US) | 2001-11-28 | — | — | CN | claimed |
| CN-119836434-A | Anti-SARS-CoV-2 antigen binding polypeptides, polypeptide complexes, and methods of use thereof | 摩德斯医疗股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-114447333-B | Sodium ion battery | 天津中电新能源研究院有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-116615450-A | Human monoclonal antibody against SARS-COV-2 and application thereof | UAB研究基金会 | 2023-08-18 | — | — | CN | disclosed |
| US-7109184-B2 | Phosphate transport inhibitors | GENZYME CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1485391-B1 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORP (US) | 2006-08-23 | — | — | EP | disclosed |
| CN-1217698-C | Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents | MAXIN PHARMACEUTICALS INC (US) | 2005-09-07 | — | — | CN | disclosed |
| EP-1485391-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20040019020-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003080630-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-10-02 | — | — | WO | disclosed |
| CN-1324245-A | Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents | MAXIN PHARMACEUTICALS INC (US) | 2001-11-28 | — | — | CN | disclosed |
| WO-1996019486-A1 | CERTAIN TETRAZOLE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-27 | — | — | WO | disclosed |